Unknown

Dataset Information

Sphingomyelin nanosystems loaded with uroguanylin and etoposide for treating metastatic colorectal cancer.


ABSTRACT: Colorectal cancer is the third most frequently diagnosed cancer malignancy and the second leading cause of cancer-related deaths worldwide. Therefore, it is of utmost importance to provide new therapeutic options that can improve survival. Sphingomyelin nanosystems (SNs) are a promising type of nanocarriers with potential for association of different types of drugs and, thus, for the development of combination treatments. In this work we propose the chemical modification of uroguanylin, a natural ligand for the Guanylyl Cyclase (GCC) receptor, expressed in metastatic colorectal cancer tumors, to favour its anchoring to SNs (UroGm-SNs). The anti-cancer drug etoposide (Etp) was additionally encapsulated for the development of a combination strategy (UroGm-Etp-SNs). Results from in vitro stud

SUBMITTER: Bouzo BL 

PROVIDER: S-EPMC8390746 | biostudies-literature | 2021 Aug

REPOSITORIES: biostudies-literature